| Document Date: 2011-09-13 08:24:17
Open Document File Size: 956,24 KBShare Result on Facebook
City Rochester / Cary / Palermo / Lyon / / Company Cox / GE / / Country France / Italy / / / Facility Mayo Clinic / SAS Institute / Laboratory Features / Discussion The Mayo Clinic / / MedicalCondition post-essential thrombocythemia myelofibrosis / polycythemia vera / intermediate-/high-risk myelofibrosis / Leukemia / thrombocytosis / agnogenic myeloid metaplasia / Cancer / JE / Tefferi A. Myelofibrosis / disease / neoplasm / essential thrombocythemia / blast phase / bone marrow fibrosis / low-risk disease / myeloid neoplasms / myeloproliferative disorders / primary myelofibrosis / idiopathic myelofibrosis / myeloid metaplasia / fatigue / Flandrin G. Chronic idiopathic myelofibrosis / post-polycythemia vera / myeloproliferative neoplasms / Tefferi A. Essential thrombocythemia / anemia / osteosclerosis / myelofibrosis / Tumours / hematologic malignancy / / MedicalTreatment radiation therapy / investigational therapy / drug therapy / surgery / / Organization World Health Organization / Mayo Foundation / Fred Hutchinson Cancer Research Center / International Agency for Research / / Person Susan M. Schwager / Jocelin Huang / Kebede Hussein / Curtis A. Hanson / Ayalew Tefferi / Sergio Siragusa / Mayo Clin Proc / / / Position representative / / Product hydroxyurea / danazol / / ProvinceOrState Minnesota / / Technology radiation / transplantation / / URL www.mayoclinicproceedings.com / /
SocialTag |
Brief Report Survival of Patients With PMF Mature Survival Data for 176 Patients Younger Than 60 Years With Primary Myelofibrosis Diagnosed Between 1976 and 2005: